Haemonetics says FDA clears vascular closure device

By Reuters News

Oct 19 (Reuters) - Haemonetics HAE.N said on Monday the US Food and Drug Administration approved its device designed to seal arterial openings created during minimally invasive heart and vascular procedures.

Shares of the medical technology company rose about 1.2% in extended trading.

  • The device, PerQseal Elite, uses a fully absorbable patch that dissolves over time and does not leave a permanent implant in the body

  • Haemonetics obtained the technology as part of its January 2026 acquisition of Ireland-based Vivasure Medical

  • FDA's approval covers use of the device with large access sheaths commonly used in structural heart and endovascular procedures

  • Haemonetics said physicians can confirm if bleeding has stopped without losing guidewire access during the procedure

  • The company also said it will present additional clinical data at the Transcatheter Cardiovascular Therapeutics conference later this month

  • Haemonetics sells blood collection, blood management and interventional medical products, including vascular closure technologies used in cardiovascular procedures

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.